Alloantigen gene transfer to hepatocytes promotes tolerance to pancreatic islet graft by inducing CD8+ regulatory T cells

Journal of Hepatology

Volumn 66, Issue 4, 2017, Pages 765-777

  Le Guen, Valentin ^a,b   Judor, Jean Paul ^a,b   Boeffard, Françoise ^a,b   Gauttier, Vanessa ^a,b   Ferry, Nicolas ^c   Soulillou, Jean Paul ^a,b   Brouard, Sophie ^a,b   Conchon, Sophie ^a,b  

^a UNIVERSITÉ DE NANTES   (France)

^b NANTES UNIVERSITY HOSPITAL   (France)

^c SAINT LOUIS HOSPITAL   (France)

Author keywords

Allogeneic transplantation; Gene transfer; Liver immunology; Tolerance induction

Indexed keywords

ADENOVIRUS VECTOR; ALANINE AMINOTRANSFERASE; ALLOANTIGEN; ANTIBODY; ASPARTATE AMINOTRANSFERASE; CD28 ANTIGEN; CD3 ANTIGEN; CD4 ANTIGEN; CYTOCHROME P450 2B4; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DONOR SPECIFIC ANTIBODY; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 2 RECEPTOR BETA; LAG 3 PROTEIN; MACROPHAGE DERIVED CHEMOKINE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MONOCYTE CHEMOTACTIC PROTEIN 1; PROGRAMMED DEATH 1 LIGAND 1; PROTEIN; T LYMPHOCYTE RECEPTOR BETA CHAIN; TRANSCRIPTION FACTOR FOXP3; UNCLASSIFIED DRUG; H-2K(K) ANTIGEN; H2 ANTIGEN;

ADOPTIVE TRANSFER; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALLOGRAFT; ALLOTRANSPLANTATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN PRESENTING CELL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CD8+ T LYMPHOCYTE; CELL EXPANSION; CELL PROLIFERATION; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE RELEASE; DOWN REGULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GENE OVEREXPRESSION; GENE TRANSFER; GRAFT RECIPIENT; GRAFT REJECTION; GRAFT SURVIVAL; HUMORAL IMMUNITY; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL; LIVER HISTOLOGY; LONG TERM SURVIVAL; MALE; MEDIAN SURVIVAL TIME; MEMORY T LYMPHOCYTE; MIXED LYMPHOCYTE REACTION; MOUSE; NATURAL KILLER T CELL; NONHUMAN; OVERALL SURVIVAL; PANCREAS ISLET; PANCREAS ISLET TRANSPLANTATION; PANCREATIC ISLET GRAFT; PHENOTYPE; PRIORITY JOURNAL; PROMOTER REGION; REGULATORY T LYMPHOCYTE; SPLEEN CELL; STABLE EXPRESSION; STREPTOZOTOCIN-INDUCED DIABETES MELLITUS; T LYMPHOCYTE SUBPOPULATION; TISSUE GRAFT; UPREGULATION; VACCINATION; ANIMAL; BAGG ALBINO MOUSE; C3H MOUSE; C57BL MOUSE; DONOR; EXPERIMENTAL DIABETES MELLITUS; GENE VECTOR; GENETICS; IMMUNOLOGY; IMMUNOSUPPRESSIVE TREATMENT; PARVOVIRINAE; PROCEDURES; TRANSGENIC MOUSE;

ADOPTIVE TRANSFER; ANIMALS; DIABETES MELLITUS, EXPERIMENTAL; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; GRAFT SURVIVAL; H-2 ANTIGENS; HEPATOCYTES; IMMUNOSUPPRESSION; ISLETS OF LANGERHANS TRANSPLANTATION; ISOANTIGENS; MALE; MICE; MICE, INBRED BALB C; MICE, INBRED C3H; MICE, INBRED C57BL; MICE, TRANSGENIC; PARVOVIRINAE; T-LYMPHOCYTES, REGULATORY; TISSUE DONORS; TRANSPLANTATION, HOMOLOGOUS;

EID: 85009728755     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2016.11.019     Document Type: Article

References (58)

1. [1] Fishman, J.A., Infection in solid-organ transplant recipients. N Engl J Med 357 (2007), 2601–2614.
2. [2] Euvrard, S., Morelon, E., Rostaing, L., Goffin, E., Brocard, A., Tromme, I., et al. Sirolimus and secondary skin-cancer prevention in kidney transplantation. N Engl J Med 367 (2012), 329–339.
3. [3] Scandling, J.D., Busque, S., Dejbakhsh-Jones, S., Benike, C., Millan, M.T., Shizuru, J.A., et al. Tolerance and chimerism after renal and hematopoietic-cell transplantation. N Engl J Med 358 (2008), 362–368.
4. [4] Leventhal, J., Abecassis, M., Miller, J., Gallon, L., Ravindra, K., Tollerud, D.J., et al. Chimerism and tolerance without GVHD or engraftment syndrome in HLA-mismatched combined kidney and hematopoietic stem cell transplantation. Sci Transl Med, 4, 2012, 124ra28.
5. [5] Kawai, T., Sachs, D.H., Sprangers, B., Spitzer, T.R., Saidman, S.L., Zorn, E., et al. Long-term results in recipients of combined HLA-mismatched kidney and bone marrow transplantation without maintenance immunosuppression. Am J Transplant 14 (2014), 1599–1611.
6. [6] Geissler, E.K., Hutchinson, J.A., Cell therapy as a strategy to minimize maintenance immunosuppression in solid organ transplant recipients. Curr Opin Organ Transplant, 2013, 1–8.
7. [7] Tang, Q., Bluestone, J.A., Regulatory T-cell therapy in transplantation: moving to the clinic. Cold Spring Harb Perspect Med, 3, 2013 pii: a015552.
8. [8] Sagoo, P., Ali, N., Garg, G., Nestle, F.O., Lechler, R.I., Lombardi, G., Human regulatory T cells with alloantigen specificity are more potent inhibitors of alloimmune skin graft damage than polyclonal regulatory T cells. Sci Transl Med, 3, 2011, 83ra42.
9. [9] Farris, A.B., Taheri, D., Kawai, T., Fazlollahi, L., Wong, W., Tolkoff-Rubin, N., et al. Acute renal endothelial injury during marrow recovery in a cohort of combined kidney and bone marrow allografts. Am J Transplant 11 (2011), 1464–1477.
10. [10] Sachs, D.H., Sykes, M., Kawai, T., Cosimi, A.B., Immuno-intervention for the induction of transplantation tolerance through mixed chimerism. Semin Immunol 23 (2011), 165–173.
11. [11] Putnam, A.L., Safinia, N., Medvec, A., Laszkowska, M., Wray, M., Mintz, M.A., et al. Clinical grade manufacturing of human alloantigen-reactive regulatory T cells for use in transplantation. Am J Transplant 13 (2013), 3010–3020.
12. [12] Crispe, I.N., Immune tolerance in liver disease. Hepatology 60 (2014), 2109–2117.
13. [13] Jacob, A.I., Goldberg, P.K., Bloom, N., Degenshein, G.A., Kozinn, P.J., Endotoxin and bacteria in portal blood. Gastroenterology 72 (1977), 1268–1270.
14. [14] Knolle, P.A., Thimme, R., Hepatic immune regulation and its involvement in viral hepatitis infection. Gastroenterology 146 (2014), 1193–1207.
15. [15] Heymann, F., Tacke, F., Immunology in the liver – from homeostasis to disease. Nat Rev Gastroenterol Hepatol 13 (2016), 88–110.
16. [16] Bertolino, P., Bowen, D.G., McCaughan, G.W., de St, Fazekas, Groth, B., Antigen-specific primary activation of CD8+ T cells within the liver. J Immunol 166 (2001), 5430–5438.
17. [17] Warren, A., Le Couteur, D.G., Fraser, R., Bowen, D.G., McCaughan, G.W., Bertolino, P., T lymphocytes interact with hepatocytes through fenestrations in murine liver sinusoidal endothelial cells. Hepatology 44 (2006), 1182–1190.
18. [18] Stross, L., Günther, J., Gasteiger, G., Asen, T., Graf, S., Aichler, M., et al. Foxp3+ regulatory T cells protect the liver from immune damage and compromise virus control during acute experimental hepatitis B virus infection in mice. Hepatology 56 (2012), 873–883.
19. [19] Nathwani, A.C., Reiss, U.M., Tuddenham, E.G.D., Rosales, C., Chowdary, P., McIntosh, J., et al. Long-term safety and efficacy of factor IX gene therapy in hemophilia B. N Engl J Med 371 (2014), 1994–2004.
20. [20] Lüth, S., Huber, S., Schramm, C., Buch, T., Zander, S., Stadelmann, C., et al. Ectopic expression of neural autoantigen in mouse liver suppresses experimental autoimmune neuroinflammation by inducing antigen-specific Tregs. J Clin Invest 118 (2008), 3403–3410.
21. [21] Akbarpour, M., Goudy, K.S., Cantore, A., Russo, F., Sanvito, F., Naldini, L., et al. Insulin B chain 9–23 gene transfer to hepatocytes protects from type 1 diabetes by inducing Ag-specific FoxP3+ Tregs. Sci Transl Med, 7, 2015, 289ra81.
22. [22] Cany, J., Avril, A., Pichard, V., Aubert, D., Ferry, N., Conchon, S., A transgenic mouse with β-Galactosidase as a fetal liver self-antigen for immunotherapy studies. J Hepatol 47 (2007), 396–403.
23. [23] Mai, H.-L., Boeffard, F., Longis, J., Danger, R., Martinet, B., Haspot, F., et al. IL-7 receptor blockade following T cell depletion promotes long-term allograft survival. J Clin Invest 124 (2014), 1723–1733.
24. [24] Seglen, P.O., Preparation of isolated rat liver cells. Methods Cell Biol 13 (1976), 29–83.
25. [25] Gauttier, V., Judor, J.-P., Le Guen, V., Cany, J., Ferry, N., Conchon, S., Agonistic anti-CD137 antibody treatment leads to antitumor response in mice with liver cancer. Int J Cancer 135 (2014), 2857–2867.
26. [26] Jiang, X., Shen, C., Rey-Ladino, J., Yu, H., Brunham, R.C., Characterization of murine dendritic cell line JAWS II and primary bone marrow-derived dendritic cells in Chlamydia muridarum antigen presentation and induction of protective immunity. Infect Immun 76 (2008), 2392–2401.
27. [27] Urbani, S., Amadei, B., Tola, D., Massari, M., Schivazappa, S., Missale, G., et al. PD-1 expression in acute hepatitis C virus (HCV) infection is associated with HCV-specific CD8 exhaustion. J Virol 80 (2006), 11398–11403.
28. [28] Zehn, D., Utzschneider, D.T., Thimme, R., Immune-surveillance through exhausted effector T-cells. Curr Opin Virol 16 (2016), 49–54.
29. [29] Wherry, E.J., Ha, S.-J., Kaech, S.M., Haining, W.N., Sarkar, S., Kalia, V., et al. Molecular signature of CD8+ T cell exhaustion during chronic viral infection. Immunity 27 (2007), 670–684.
30. [30] Mingozzi, F., Liu, Y.-L., Dobrzynski, E., Kaufhold, A., Liu, J.H., Wang, Y., et al. Induction of immune tolerance to coagulation factor IX antigen by in vivo hepatic gene transfer. J Clin Invest 111 (2003), 1347–1356.
31. [31] Brown, B.D., Venneri, M.A., Zingale, A., Sergi Sergi, L., Naldini, L., Endogenous microRNA regulation suppresses transgene expression in hematopoietic lineages and enables stable gene transfer. Nat Med 12 (2006), 585–591.
32. [32] Breous, E., Somanathan, S., Vandenberghe, L.H., Wilson, J.M., Hepatic regulatory T cells and Kupffer cells are crucial mediators of systemic T cell tolerance to antigens targeting murine liver. Hepatology 50 (2009), 612–621.
33. [33] Murillo, O., Luqui, D.M., Gazquez, C., Martinez-Espartosa, D., Navarro-Blasco, I., Monreal, J.I., et al. Long-term metabolic correction of Wilson's disease in a murine model by gene therapy. J Hepatol 64 (2016), 419–426.
34. [34] Cunningham, E.C., Tay, S.S., Wang, C., Rtshiladze, M., Wang, Z.Z., McGuffog, C., et al. Gene therapy for tolerance: high-level expression of donor major histocompatibility complex in the liver overcomes naive and memory alloresponses to skin grafts. Transplantation 95 (2013), 70–77.
35. [35] Cooper, M., Nayak, S., Hoffman, B.E., Terhorst, C., Cao, O., Herzog, R.W., Improved induction of immune tolerance to factor IX by hepatic AAV-8 gene transfer. Hum Gene Ther 20 (2009), 767–776.
36. [36] Isogawa, M., Chung, J., Murata, Y., Kakimi, K., Chisari, F.V., CD40 activation rescues antiviral CD8+ T cells from PD-1-mediated exhaustion. PLoS Pathog, 9, 2013, e1003490.
37. [37] Hamid, O., Carvajal, R.D., Anti-programmed death-1 and anti-programmed death-ligand 1 antibodies in cancer therapy. Expert Opin Biol Ther 13 (2013), 847–861.
38. [38] Vo, M., Holz, L.E., Wong, Y.C., English, K., Benseler, V., McGuffog, C., et al. The extent and duration of acute hepatitis in mice is dominated by the function rather than by the survival of effector CD8 T cells. J Hepatol, 2016, 1–43.
39. [39] Fuller, M.J., Callendret, B., Zhu, B., Freeman, G.J., Hasselschwert, D.L., Satterfield, W., et al. Immunotherapy of chronic hepatitis C virus infection with antibodies against programmed cell death-1 (PD-1). Proc Natl Acad Sci U S A 110 (2013), 15001–15006.
40. [40] Gardiner, D., Lalezari, J., Lawitz, E., DiMicco, M., Ghalib, R., Reddy, K.R., et al. A randomized, double-blind, placebo-controlled assessment of BMS-936558, a fully human monoclonal antibody to programmed death-1 (PD-1), in patients with chronic hepatitis C virus infection. PLoS One, 8, 2013, e63818.
41. [41] Wherry, E.J., Kurachi, M., Molecular and cellular insights into T cell exhaustion. Nat Rev Immunol 15 (2015), 486–499.
42. [42] Wherry, E.J., T cell exhaustion. Nat Immunol 12 (2011), 492–499.
43. [43] Shin, H., Blackburn, S.D., Blattman, J.N., Wherry, E.J., Viral antigen and extensive division maintain virus-specific CD8 T cells during chronic infection. J Exp Med 204 (2007), 941–949.
44. [44] Liu, W., Putnam, A.L., Xu-Yu, Z., Szot, G.L., Lee, M.R., Zhu, S., et al. CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells. J Exp Med 203 (2006), 1701–1711.
45. [45] Kim, H.-J., Barnitz, R.A., Kreslavsky, T., Brown, F.D., Moffett, H., Lemieux, M.E., et al. Stable inhibitory activity of regulatory T cells requires the transcription factor Helios. Science 350 (2015), 334–339.
46. [46] Kim, H.-J., Verbinnen, B., Tang, X., Lu, L., Cantor, H., Inhibition of follicular T-helper cells by CD8(+) regulatory T cells is essential for self tolerance. Nature 467 (2010), 328–332.
47. [47] Dai, Z., Zhang, S., Xie, Q., Wu, S., Su, J., Li, S., et al. Natural CD8+CD122+ T cells are more potent in suppression of allograft rejection than CD4+CD25+ regulatory T cells. Am J Transplant 14 (2014), 39–48.
48. [48] Gagliani, N., Jofra, T., Stabilini, A., Valle, A., Atkinson, M., Roncarolo, M.G., et al. Antigen-specific dependence of Tr1-cell therapy in preclinical models of islet transplant. Diabetes 59 (2010), 433–439.
49. [49] Kendal, A.R., Waldmann, H., Infectious tolerance: therapeutic potential. Curr Opin Immunol 22 (2010), 560–565.
50. [50] Benichou, G., Direct and indirect antigen recognition: the pathways to allograft immune rejection. Front Biosci 4 (1999), D476–D480.
51. [51] Zaiss, A.-K., Liu, Q., Bowen, G.P., Wong, N.C.W., Bartlett, J.S., Muruve, D.A., Differential activation of innate immune responses by adenovirus and adeno-associated virus vectors. J Virol 76 (2002), 4580–4590.
52. [52] Tay, S.S., Wong, Y.C., McDonald, D.M., Wood, N.A.W., Roediger, B., Sierro, F., et al. Antigen expression level threshold tunes the fate of CD8 T cells during primary hepatic immune responses. Proc Natl Acad Sci U S A 111 (2014), E2540–E2549.
53. [53] Wong, Y.C., Tay, S.S., McCaughan, G.W., Bowen, D.G., Bertolino, P., Immune outcomes in the liver: is CD8 T cell fate determined by the environment?. J Hepatol 63 (2015), 1005–1014.
54. [54] Wood, K.J., Sakaguchi, S., Regulatory T cells in transplantation tolerance. Nat Rev Immunol 3 (2003), 199–210.
55. [55] Kusaka, S., Grailer, A.P., Fechner, J.H., Jankowska-Gan, E., Oberley, T., Sollinger, H.W., et al. Clonotype analysis of human alloreactive T cells: a novel approach to studying peripheral tolerance in a transplant recipient. J Immunol 164 (2000), 2240–2247.
56. [56] Guillonneau, C., Hill, M., Hubert, F.-X., Chiffoleau, E., Hervé, C., Li, X.-L., et al. CD40Ig treatment results in allograft acceptance mediated by CD8CD45RC T cells, IFN-gamma, and indoleamine 2,3-dioxygenase. J Clin Invest 117 (2007), 1096–1106.
57. [57] Braun, C.J., Boztug, K., Paruzynski, A., Witzel, M., Schwarzer, A., Rothe, M., et al. Gene therapy for Wiskott-Aldrich syndrome–long-term efficacy and genotoxicity. Sci Transl Med, 6, 2014, 227ra33.
58. [58] Naldini, L., Gene therapy returns to centre stage. Nature 526 (2015), 351–360.